Lucid Diagnostics : Corporate Presentation - March 2024
April 03, 2024 at 12:58 pm
Share
Nasdaq: LUCD
EsoGuard Esophageal Precancer Testing:
A Breakthrough in Cancer Prevention
March 20, 2024
Lishan Aklog MD
Chairman & CEO
Disclaimer
This presentation may contain certain forward-looking statements related to or Lucid Diagnostics Inc. (the "Company") that involve risks and uncertainties.
Actual results and events may differ significantly from results and events discussed in forward- looking statements.
Factors that might cause or contribute to such differences include, but are not limited to, those discussed in "Risk Factors" in the Company's Annual Reports on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.
The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made.
This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
The Company may not yet have received clearance from the FDA or any other regulatory agency for some of the products described in this presentation.
2
Nasdaq: LUCD
Commercial-stage Cancer Prevention Medical Diagnostics Company
Focused on Early Precancer Detection
MISSION: Prevent Esophageal Cancer Deaths in At-risk Patients
3
High margin asset with
massive market
opportunity
Well-honedmulti-pronged
commercial strategy
Operationally excellent
multidisciplinary field and
laboratory team
World-class leadership team, board and advisors
4
Nasdaq: LUCD
Capitalization
LUCD Common Stock
Conversion
48.2M
Price
OUT ST ANDING
Options
$1.74 (avg.)
8.4M
SECURIT IES
Series B Preferred Stock 44,285 shares
$1.24
35.6M
Secured Convertible Debt
$5.00
2.2M
Total
94.4M
MARKET
Undiluted
$51M
CAPIT ALIZ AT ION
Fully diluted (Mar 25, 2024; $1.06/shr)
$100M
Cash 4Q23 ProForma (incl Mar'24 Series B Preferred per above)
$36.3M
Avg Quarterly Burn Rate thru 4Q23
$8.2M
5
Nasdaq: LUCD
Investment Thesis
First and only commercially available product addressing large unmet clinical need to prevent esophageal cancer deaths through early precancer detection in well-defined target population as recommended by society guidelines
~$60B total addressable market (TAM) with established test pricing and high margins
Unprecedented diagnostic performance, particularly for early precancer detection
Growing test volume and near-termreimbursement inflection points, with line of sight to CMS and commercial coverage
Large additional revenue opportunity through direct contracting, offering test
as covered health and wellness benefit
6
The
Deadly
Three
5-Year
Cancer Survival
Overall
Early
Stage
Pancreatic
13%
44%
Esophageal
22%
49%
Liver
22%
37%
Esophageal PRECANCER can now be detected
7
Esophageal Cancer - A Ruthless Killer
Over
Incidence Increase
500%
Since 1975
21,560
2023 US Esophageal Cancer Diagnoses
8
Esophageal Cancer
CAN be…
PREVENTED
9
EsoGuard® Esophageal DNA Test
First and only commercially available test capable of serving as a widespread screening tool to prevent esophageal cancer deaths through early detection of
esophageal precancer
10
Attachments
Original Link
Original Document
Permalink
Disclaimer
Lucid Diagnostics Inc. published this content on
03 April 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
03 April 2024 16:57:03 UTC.
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The Companyâs products include EsoGuard, and EsoCheck. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device that allows a clinician to treat dysplastic BE before it can progress to EAC.